you don't know why either - you also don't seem to understand that (1) efficacy ultimately sells drugs - not sheer #'s of sales reps (2) you also don't seem to be able to understand that a more potent drug that is has much higher affinity and is much more selective can be more efficacy and safer
you also seem to think that lunesta will be able to be sold once somebody in the media gets a hold of that FDA form info with the neoplasia rates of 5+ % and the mutagenicity in animals
If you did your home work Lunesta has as good a label as it gets and at this point a real label, Indiplon has no approved label for comparison, your comments are just more fluff, The battle will be about marketing, plain and simple and it will be a crowded space by FY09.
oh! the big stock investment guy can't tell the world why pfizer pulled the plug before Indiplon FDA meeting after spending $500M on this program. Please also tell us why the pipeline is worth $30 as you have stated in several post with your fluffy statements, give me details on how you get to that number not fluff. The bottom line pinhead is just a faceless pumper who bought the stock at $20